Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation
Status:
Not yet recruiting
Trial end date:
2028-10-30
Target enrollment:
Participant gender:
Summary
Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and
randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile.
The primarily outcome measure will be carotid plaque volume change over 6 months; secondary
outcome measures will be plaque inflammatory activity and coronary microvascular function.